HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational-signatures

Approximately 1-5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Germline and/or somatic mutations in BRCA1/BRCA2 in other cancer types also confer selective sensitivity to PARP inhibitors. T...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Med
Autores principales: Davies, Helen, Glodzik, Dominik, Morganella, Sandro, Yates, Lucy R., Staaf, Johan, Zou, Xueqing, Ramakrishna, Manasa, Martin, Sancha, Boyault, Sandrine, Sieuwerts, Anieta M., Simpson, Peter T., King, Tari A., Raine, Keiran, Eyfjord, Jorunn E., Kong, Gu, Borg, Åke, Birney, Ewan, Stunnenberg, Hendrik G., van de Vijver, Marc J., Børresen-Dale, Anne-Lise, Martens, John W.M., Span, Paul N., Lakhani, Sunil R, Vincent-Salomon, Anne, Sotiriou, Christos, Tutt, Andrew, Thompson, Alastair M., Van Laere, Steven, Richardson, Andrea L., Viari, Alain, Campbell, Peter J, Stratton, Michael R., Nik-Zainal, Serena
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833945/
https://ncbi.nlm.nih.gov/pubmed/28288110
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4292
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares